Introduction {#sec1}
============

Gene therapy for X-linked severe combined immunodeficiency (SCID-X1) has been successfully employed in the clinic by restoration of γc expression in bone-marrow-derived CD34^+^ cells using integrating vectors.[@bib1], [@bib2] In the earliest studies, using conventional γ-retroviral vectors, robust immune reconstitution was observed in the majority of infants, likely owing to the selective advantage of the transduced progenitors. However, despite successful phenotypic correction, 25% of treated infants developed T cell acute lymphoblastic leukemia (T-ALL) as a consequence of insertional mutagenesis. Furthermore, patients acquired secondary genomic abnormalities including activating mutations in *NOTCH1*.[@bib3], [@bib4] Although the role of insertional mutagenesis via the activation of proto-oncogenes such as *LMO2* has been clearly implicated in the development of T-ALL in SCID-X1 patients following gene therapy, the absence of adverse events in patients treated similarly for adenosine deaminase deficiency (ADA-SCID), despite also exhibiting integrations near these proto-oncogenes, remains incompletely understood.

We have previously developed a mouse model of lentivirus-mediated correction of SCID-X1 and observed lymphoid malignancies.[@bib5] Crucially, the oncogenic events observed in mice receiving gene therapy were not attributable to insertional mutagenesis, suggesting alternative mechanisms for genotoxic risk in this model. One significant difference between positive control SCID-X1 mice reconstituted with wild-type hematopoietic progenitor cells and SCID-X1 mice receiving gene therapy with an equivalent number of vector-exposed γc-deficient progenitor cells was the absolute number of cells received that were competent for lymphoid reconstitution. The gene therapy group received a lower dose on account of only a subset of vector-exposed γc-deficient cells being transduced. We therefore hypothesized that reconstitution of SCID-X1 mice with limiting numbers of hematopoietic progenitor cells might be a risk factor for lymphoid malignancy.

In the current study, we sought to explore the relationship between hematopoietic progenitor cell dose and the incidence of lymphoid malignancy by transplanting sub-lethally irradiated γc^−/−^Rag^−/−^ mice with serially fewer wild-type Sca1^+^ progenitor cells, in the absence of gene transfer. The progenitor cell doses examined fell within a range that supported immunological reconstitution, and the resultant lymphoid compartment sizes varied by no more than ∼2-fold, despite up to 100-fold differences in hematopoietic progenitor cell dose. Of greatest interest, however, was the observation of a robust inverse correlation between cell dose and the incidence of T-lymphoid malignancy, with progressively shorter disease latency at lower cell doses. All malignancies were wild-type donor cell-derived and carried activating *Notch1* mutations.

Replicative stress has been implicated in the development of B cell leukemia in mice[@bib6] and is a plausible antecedent to T-lymphoid oncogenesis in the current study. While encompassing this possibility, our findings fall within a conceptual framework provided by recent insights into murine thymocyte biology. Most notable among these is the observation of sustained thymic output despite complete T cell progenitor deprivation (thymus autonomy), with autonomous T cell production being supported by induction of a thymocyte self-renewal phenotype.[@bib7], [@bib8], [@bib9], [@bib10] This self-renewal phenotype, which arises in the double-negative (DN) 3 thymic niche and can also be induced by deliberate *Lmo2* overexpression,[@bib11] appears to carry an inherent risk of oncogenesis that is dependent upon acquisition of additional genetic lesions, such as *Notch1* mutations. Moreover, competition from bone-marrow-derived progenitors has been shown to increase the turnover of thymocytes with a self-renewal phenotype, thereby reducing the probability of acquiring oncogenic mutations.[@bib10] Directly relevant to the SCID-X1 phenotype is the inability of γc-deficient thymic progenitors to progress to the DN3 niche, thereby reducing their ability to provide competition to γc-proficient progenitors.[@bib9] Thus, data generated in our model are consistent with limiting thymic precursor supply, not only inducing a self-renewal phenotype in the murine thymus, but also simultaneously reducing competition in the DN3 niche with a resultant cell dose-dependent increase in oncogenic risk.

There is currently no evidence that limiting thymic precursor supply is a risk factor for lymphoid malignancy in humans; nevertheless, the possibility of cell competition acting as a tumor suppressor mechanism in the human thymus following vector-mediated insertional oncogene activation remains a compelling hypothesis. Coupled with disease-specific differences in the progression of thymic precursors through T cell ontogeny, this hypothesis has the potential to help explain differing risks of oncogenesis.

Results {#sec2}
=======

The Frequency of Lymphoid Malignancy Is Inversely Proportional to the Wild-Type Progenitor Cell Dose Used to Reconstitute SCID-X1 Mice {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------------

To explore the notion that limiting thymic precursor supply is a risk factor for oncogenesis, sub-lethally irradiated γc^−/−^Rag2^−/−^ recipients were reconstituted with different doses of wild-type bone marrow hematopoietic progenitor cells ([Figure 1](#fig1){ref-type="fig"}A). We chose to use γc^−/−^Rag2^−/−^ recipients because IL2RG^−/−^ mice have been shown to have a "leaky" T cell phenotype that manifests with age[@bib12] and would therefore not be suitable for longitudinal studies. Importantly, however, the donor cells were IL2RG^−/−^. To ensure all mice received an equivalent cell dose, the total cell number was fixed at 5 × 10^5^ per recipient animal, and, at the lower cell doses, Sca1^+^ progenitor cells from IL2RG^−/−^ mice (γc null) were combined with those expressing γc; 5 × 10^5^ (high dose), 5 × 10^4^ (mid dose) or 5 × 10^3^ (low dose), with the latter two doses representing a phenocopy of 10% and 1% gene transfer, respectively. In this model, only wild-type cells are capable of progressing past the double-negative 2 (DN2) stage of thymic development.

To investigate long-term oncogenic risk, mice reconstituted with a high, mid, or low dose of γc-expressing progenitors were observed for up to 18 months. Lymphoid malignancies were never observed in mice receiving the high dose, consistent with our previous study[@bib5] but detected exclusively in animals from the mid- and low-dose groups between 6.6 and 17.6 months post-transplantation ([Figure 1](#fig1){ref-type="fig"}B). The latency for oncogenesis was also significantly longer in the mid-dose group compared with low-dose group (12.8 ± 3.5 and 8.9 ± 1.4 months, respectively; p = 0.02). Of the 31 mice that had received the mid cell dose, four developed malignancy, while the incidence of malignancy was not significantly greater than in mice transplanted with the high dose of progenitors, the survival rate was decreased (p = 0.03). In the low-dose group, both the incidence of malignancy and malignancy-free survival rates were significantly different when compared with the high-dose group (p = 0.0017 and p = 0.0001, respectively). Of interest, the rate of malignancy in mice transplanted with the low dose of γc-expressing cells (33.3%) was similar to that observed in our previous study (28.6%).[@bib5]

Phenotypic Characterization of Leukemic Clones {#sec2.2}
----------------------------------------------

Necropsy showed hepatosplenomegaly with extensive blast infiltration, and histological analysis revealed marked disruption of tissue architecture in the liver, spleen, thymus ([Figure 1](#fig1){ref-type="fig"}C), lung, and kidney (data not shown). Interestingly, enlarged thymi containing malignant cells were almost exclusively present in mice transplanted with the lowest dose of γc-expressing progenitors, which was in contrast to mice that developed malignancy from the mid dose group, where the thymus was small or, in most cases, not macroscopically visible ([Table 1](#tbl1){ref-type="table"}).

Abnormal T cell populations in 12 of the 14 mice that developed malignancy were identified in the spleen, liver, thymus, bone marrow, and peripheral blood. White blood cell counts were also elevated in these animals. The phenotypes of these tumors were diverse, with cells expressing immature, mature, and atypical combinations of surface markers ([Table 1](#tbl1){ref-type="table"}). In addition, two of the 14 malignancies (14.3%) did not express the T cell markers CD3, CD4, or CD8 and were B220 positive (m249 and m250).

Limiting Thymic Precursor Supply Did Not Prevent Reconstitution of the Immunological Compartment {#sec2.3}
------------------------------------------------------------------------------------------------

Peripheral blood assessed at 6 (data not shown) and 16 weeks post-transplantation ([Figure 2](#fig2){ref-type="fig"}A) demonstrated lymphoid reconstitution with all three doses, with T, B, and natural killer (NK) cell compartments observed at the expected ratios. Lymphoid reconstitution for mice receiving the mid dose of γc-expressing cells was only approximately half (47%) that of animals receiving the high cell dose, despite receiving 10-fold fewer γc-expressing cells. For mice receiving the lowest dose of γc-expressing cells, lymphoid reconstitution was comparable to that of mice receiving the mid dose, and when compared to mice receiving the high dose of wild-type cells (i.e., 100-fold more γc-expressing cells), the lymphoid compartment was reduced to only 43%.

The level of bone marrow chimerism in mice reconstituted with either the high or low dose of wild-type (CD45.1 positive) progenitors was determined by flow cytometry. The contribution of wild-type cells was found to be 64.9% ± 3.0% (n = 8) in the high-dose group, indicating that the majority of cells engrafted in the bone marrow were derived from the wild-type γc-expressing progenitors. For animals transplanted with the low dose of wild-type cells, the contribution was 3.4% ± 0.3% (n = 7), consistent with only 1% of the transplanted cells expressing γc.

T Cell Receptor Diversity Is Maintained under Conditions of Limiting Thymic Precursor Supply {#sec2.4}
--------------------------------------------------------------------------------------------

To determine whether T cell receptor (TCR) diversity was affected by limiting thymic precursor supply, TCR V~β~ repertoire and spectratype analyses (on selected highly expressed TCR V~β~ families) were performed at 15 weeks post-transplantation. Analysis of the TCR V~β~ repertoire demonstrated that, for the majority of cases, both broad representation of all V~β~ families and the percentage of each V~β~ family was equivalent in peripheral blood samples taken from mice receiving each of the three γc-expressing progenitor cell doses ([Figure 2](#fig2){ref-type="fig"}B). Spectratype analysis revealed normal Gaussian distribution of peaks in mice receiving the high and mid dose of γc-expressing progenitors for the majority of TCR V~β~ families investigated ([Figure 2](#fig2){ref-type="fig"}C). For mice reconstituted with low cell numbers, the spectratypes appeared more restricted for some TCR V~β~ families. The observation of a relatively diverse TCR V~β~ repertoire for all cohorts is suggestive of increased expansion of immature T cells at the low compared with the high cell dose prior to TCRβ rearrangement.

To assess the level of thymic T cell export occurring in vivo, the number of signal joint T cell receptor excision circles (sjTRECs), a by-product of TCRα rearrangement, was quantified in sorted splenic T cell populations at 16 weeks post-transplantation ([Figure 2](#fig2){ref-type="fig"}D). The numbers of sjTRECs isolated from mice receiving the high and mid doses were similar, implying that the transplanted cells had undergone comparable cell division after TCRα rearrangement, which occurs at the double-positive (DP) stage in the thymus. In contrast, there was a modest, but statistically significant, reduction in the number of sjTRECs present in splenocytes from mice transplanted with the low dose of progenitors when compared with both the high and mid cell doses. This is indicative of increased T cell expansion in the cohort of mice receiving the low dose of γc-expressing progenitors and is consistent with the observation of similar peripheral T cell reconstitution when compared with the mid dose group ([Figure 2](#fig2){ref-type="fig"}A).

Limiting Thymic Precursor Supply Affects the Size and Composition of the Thymus {#sec2.5}
-------------------------------------------------------------------------------

We next sought to investigate the size and composition of the thymocyte population following transplantation. Thymocytes are classified into distinct stages based on expression of cell-surface markers, the earliest of which are DN for both CD4 and CD8. This DN population contains four sub-stages (DN1--DN4) identified by the level of cell-surface CD25 and CD44. Thymocytes then enter the DP stage where they are positive for both CD4 and CD8 before becoming single positive (SP; positive for either CD4 or CD8). At 6 weeks post-transplantation, for animals receiving either the high or low dose of wild-type progenitor cells, the total number of thymocytes was significantly reduced when compared to age-matched wild-type control animals not receiving bone marrow transplantation ([Figure 3](#fig3){ref-type="fig"}A). This demonstrates that transplantation even of high doses of wild-type progenitors leads to sub-physiological levels of thymocyte reconstitution. The difference between the high and low wild-type treatment groups was also significant; notably, however, the difference in the total number of thymocytes between these groups was only 7-fold, despite the 100-fold difference in the number of transplanted γc-expressing cells capable of progressing past the DN2 stage, confirmed by flow cytometry using Ly5.1 and Ly5.2 labeling to identify the γc-negative and γc-positive populations, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}), indicating increased expansion in the low-dose cohort.

The contribution of DN, DP, and SP cells in the thymus was examined by flow cytometry, which revealed a significant reduction of DP cells in transplanted animals, proportional to the number of available wild-type progenitors from the bone marrow ([Figures 3](#fig3){ref-type="fig"}B and [S2](#mmc1){ref-type="supplementary-material"}A). Interestingly, this was concomitant with a significant increase in the proportion of mature CD4^+^ and CD8^+^ SP cells, that also expressed CD3, in transplanted animals compared with wild-type controls, potentially indicating an increased need for early T cells to transition through the thymus (p \< 0.01 for comparisons between all groups). Examination of the DN compartment showed that the proportion of cells in the DN1 stage was significantly increased in animals receiving the low dose of γc-progenitors compared both with mice receiving the high progenitor cell dose and with wild-type control animals ([Figures 3](#fig3){ref-type="fig"}C and [S2](#mmc1){ref-type="supplementary-material"}B). A significant reduction was also observed for cells at the DN3 stage in mice receiving the low dose of γc-expressing progenitors.

The most evident difference between animals receiving the low dose of γc-expressing progenitors and those receiving the high progenitor dose or wild-type animals not receiving bone marrow transplantation was in the fold changes of thymocyte cell numbers within the DN niches. For the low-dose cohort, the ratio of DN2 to DN1 cells was significantly reduced ([Figure 3](#fig3){ref-type="fig"}D), possibly reflecting a rapid transition of cells from the DN2 niche, in an attempt to prevent lymphopenia in these animals. In striking contrast, there was a marked 6-fold increase in the ratio of DN4 to DN3 cells in mice receiving the low dose of γc-expressing progenitors, which may be indicative of a homeostatic mechanism to maintain the peripheral compartment size. It is possible that cells within the DN4 niche (i.e., negative for CD4, CD8, CD25, and CD44) could include progenitor cells of non-T cell lineages that reside in the thymus which may affect interpretation of DN ratios. It should also be emphasized, despite the differences observed in the relative proportion of each DN niche, particularly for animals receiving the low progenitor cell dose compared to wild-type control animals, that this is in concert with a marked reduction in the absolute number of cells in the thymus, and, therefore, all DN niches are diminished.

Molecular Characterization of Leukemic Clones {#sec2.6}
---------------------------------------------

Genomic DNA was isolated from malignant blasts of affected animals and qPCR performed using primers to detect wild-type γc sequence, with wild-type sequence accounting for between 69.7% and 97.2% of the genomic DNA sample and correlating with the majority of each sample containing malignant cells. Importantly, this confirmed that all malignancies were derived from the transplanted γc^+^ wild-type donor and not the γc-deficient donor or recipient cell populations, which is supported by the expression of T and/or B cell markers in the samples ([Table 1](#tbl1){ref-type="table"}).

Whole-genome sequencing (WGS) was performed on selected leukemic clones that contained a high proportion (≥75%) of malignant cells ([Figure 4](#fig4){ref-type="fig"}; m97, m137, m189, m191, m209, and m313) to identify potential common mutational signatures. Microarray analysis was also performed on five of the six samples (the quality of RNA for sample m137 was not sufficient for analysis). Of the 407 mouse orthologs contained in the Sanger cancer consensus genes database (<http://cancer.sanger.ac.uk/census/>), 14 (3.4%) displayed expression levels that were altered \>2-fold when compared to wild-type thymocytes (*Brca2*, *Card11*, *Ccnd1*, *Gnaq*, *Hmga1*, *Il21r*, *Itk*, *Jazf1*, *Notch1*, *Nr4a3*, *Pdgfrb*, *Recql4*, *Rel*, and *Tfrc*). All sequenced samples except m313 (adoptive transfer recipient) showed evidence of substantial copy number decreases on the X chromosome, in comparison to Sca1^+^ bone marrow progenitors. Also, substantial copy number gains on chromosome 15 were shown to be common for mice receiving the low dose of γc-positive progenitors (m137, m189, m191, and m209). This evidence is in keeping with the data of Martins et al., who had observed gains on chromosome 15.[@bib10] Interestingly, one sample (m209) also displayed large copy number gains on chromosome 14 ([Figure 4](#fig4){ref-type="fig"}).

Activating *Notch1* mutations were identified by WGS in each of the samples, comprising either a 5′ deletion or mutations within the sequence encoding the proline, glutamate, serine, and threonine (PEST) domain located in exon 34 ([Figure 5](#fig5){ref-type="fig"}A). Sanger sequencing across the affected regions confirmed these mutations and gene expression profiling by microarrays identified *Notch1* upregulation in malignant samples (3.5-fold, false discovery rate \[FDR\] adjusted p value = 0.012). Of the six samples investigated, five contained the 5′ deletion and five contained a mutation in exon 34, with four of the six samples carrying both lesions. We also observed exon 34 deletions in our previous study.[@bib5] Similar mutations have been identified in leukemia samples generated under conditions of thymic progenitor cell deprivation.[@bib10] To investigate the presence of activating mutations in the *Notch1* proto-oncogene in our other samples, DNA sequence analysis was performed across the breakpoint of the 5′ deletion as well as the PEST, transactivation (TAD), or heterodimerization (HD) domains. Further, activating *Notch1* mutations (5′ deletions and/or PEST domain mutations) were identified in the remaining tumors (those not subjected to WGS) from mice transplanted with the low dose of γc-expressing progenitors ([Table 2](#tbl2){ref-type="table"}; [Figures 5](#fig5){ref-type="fig"}B and 5C).

The impact of activating mutations in *Notch1* was investigated by using qRT-PCR directed at the downstream targets, *c-myc*, *Dtx1*, and *Hes1*. In the malignant blasts examined (n = 5), elevated levels of these transcripts were observed when compared to normal wild-type thymocytes; *c-myc*, *Dtx1*, and *Hes1* were found to be upregulated by 6.85 ± 1.80, 2.47 ± 0.54, and 2.78 ± 0.26-fold, respectively (data not shown). Upregulation of *Hes1* (9.78-fold, FDR = 0.021) and *c-myc* (3.25-fold, FDR = 0.073) in malignant blasts was also detected by microarray analysis.

Discussion {#sec3}
==========

We have identified limiting bone marrow progenitor supply to the thymus as an initiator of lymphoid malignancy in mice. Importantly, this oncogenic risk is cell dose dependent, occurs within cell dose ranges that support immunological reconstitution, and does not require the complete absence of progenitor cell migration from the bone marrow as previously observed in thymic grafting studies,[@bib8], [@bib10] making this feature of our model unique. Based on existing evidence, the mechanism underlying oncogenesis is theorized to have two critical components. The first is the induction of a transformation-prone self-renewal phenotype in a subset of thymocytes as a homeostatic response to an inadequate supply of progenitors from the bone marrow.[@bib7], [@bib8], [@bib9] The second is reduced competitive pressure on this at-risk population for thymic niche space from differentiation-committed thymocytes progressing through lymphoid ontogeny.[@bib10] The proposed combined effect would be an increase in the number and residency time of transformation-prone thymocytes, leading to a correspondingly higher probability of cells within this population being subject to oncogenic second hit events, such as activating mutations in *Notch1*.

In an effort to phenocopy gene therapy for SCID-X1 in our model system, mice were reconstituted with serially fewer wild-type bone marrow progenitor cells, used as surrogates for gene-corrected cells, against a background of γc-deficient progenitors adjusted to maintain a constant total cell dose in all treatment groups. In this context, the inverse correlation observed between the incidence of T-lymphoid malignancy and wild-type progenitor cell dose is consistent with a failure of γc-deficient cells to progress to the point in T cell ontogeny, the DN3 niche, where competitive pressure on tumor-prone self-renewing thymocytes has been hypothesized to exert a tumor-suppressive effect.[@bib10]

When we initially observed T-lymphoid oncogenesis, independent of insertional mutagenesis in our earlier gene therapy study in SCID-X1 mice,[@bib5] we favored replicative stress as a possible tumorigenic mechanism. For this reason, an effort was made to examine the differing effects of limiting progenitor cell doses on the extent and location of the homeostatic cellular expansion during T cell ontogeny by assessing TCR diversity and number sjTREC in peripheral blood T cells, although an analysis of whether there were differences in the percentages of naive and memory peripheral T cells, with an increase in the latter indicative of homeostatic proliferation under conditions of lymphopenia,[@bib13] was not performed. Despite 100-fold fewer cells capable of progression past the DN2 stage of thymic ontogeny, and competent for lymphoid ontogeny in the low-dose wild-type progenitor cell treatment group, reduction in the resultant peripheral T cell compartment size was only in the order of 2-fold. This is clearly indicative of higher levels of cellular replication during T cell ontogeny in these animals. While this represents a 50-fold change in the relative size of the input progenitor and output peripheral T cell populations, the relative difference in the absolute number of cell divisions required to achieve this, in an exponentially expanding population, is much smaller.

Accepting that the dynamics of thymic homeostasis are complex,[@bib14], [@bib15] this argues against the oncogenic risk observed at limiting progenitor cell doses being a simple function of the cumulative burden of somatic mutations acquired during individual cell division events. Data from TCR diversity and sjTREC analysis in peripheral blood and splenic T cells, respectively, also provide similar arguments supporting this point. Relatively well-preserved TCR diversity, in concert with TREC-based evidence for a 2-fold replicative expansion of T cells following TCRα rearrangement in mice receiving 100-fold fewer γc-expressing progenitors, provides evidence of homeostatic expansion both before and after the DP stage of T cell ontogeny. While this supports a 50-fold relative expansion prior to, and a 2-fold expansion after the DP stage, in an exponentially growing population, the difference in the absolute number of cell divisions occurring before and after the DP stage is likely to be relatively small. Further analyses, including whether there is increased proliferation of wild-type progenitors, compared to the immunodeficient populations, or a greater number of early thymic progenitors (ETPs) would contribute to the understanding of the extent and location of the homeostatic cellular expansion during T cell ontogeny in our model. Early thymic progenitors, identified by high levels of cKit on their surface (cKit^high^ cells), have been shown to support long-term thymopoiesis in intrathymic transplantation studies.[@bib13], [@bib16] If cell division itself was a strong risk factor for transformation, then one would expect a high proportion of such events to occur in more mature T cells, which is unsupported by existing evidence.[@bib7], [@bib8], [@bib9], [@bib10], [@bib11]

When considering the possible relevance of these murine data to the oncogenic mechanisms operative in early human SCID-X1 gene therapy trials, it is important to emphasize that murine cells are inherently more transformation-prone than human cells,[@bib17] and to our knowledge there is no evidence to suggest that limiting thymic precursor supply in humans carries oncogenic risk through the induction of thymocyte self-renewal. Indeed, based on clinical experience in allogeneic stem cell transplantation for SCID phenotypes including SCID-X1, Qasim et al. have argued against oncogenic risk being associated with a lack of bone marrow progenitor supply to the human thymus.[@bib18] They point to the absence of reports of T cell malignancy in patients with long-term thymopoiesis, despite single-lineage donor T cell recovery, which is considered indicative of thymic, but not bone marrow engraftment.

A further important point is that oncogenesis in early human clinical trials, using conventional γ-retroviral vectors to treat SCID-X1, chronic granulomatous disease (CGD),[@bib19] and Wiskott-Aldrich syndrome (WAS)[@bib20] invariably involved insertional mutagenesis, while oncogenic adverse events have not subsequently been observed with SIN γ-retroviral or SIN lentiviral vectors lacking strong viral enhancer-promoter elements. Nevertheless, we argue that insertional proto-oncogene activation in human hematopoietic progenitors, as reported in early SCID-X1 trials, is likely capable of inducing transformation-prone thymocytes. This is supported by the observation that deliberate *Lmo2* overexpression in mice can induce thymocyte self-renewal without a homeostatic drive being exerted by a limiting or absent progenitor supply.[@bib11] Once such cells arise in the human thymus, albeit by an iatrogenic mechanism, it is plausible that γc-deficient human thymic progenitors, akin to their murine counterparts, also fail to exert a tumor suppressor effect through competitive pressure. Thus, the parallels of our findings, and those of previously reported thymic transplant studies, to the human gene therapy experience occurs once the cells acquire a capacity for self-renewal, induced by either limiting precursor supply or by proto-oncogene activation. This also provides an alternative explanation for the suggested oncogenicity of γc itself that has been the topic of much debate.[@bib21], [@bib22]

An intriguing question arising from the tumor suppressor hypothesis is whether there might be disease-specific differences among disorders affecting T cell ontogeny in the capacity of thymocytes to exert tumor-suppressive effects through cell competition. For example, in gene therapy trials for ADA-SCID, using conventional γ-retroviral vectors to transduce bone-marrow-derived CD34^+^ cells, there have been no reports of T cell leukemia, despite the frequent observation of integration events in *LMO2* and other proto-oncogene loci.[@bib23] Unlike γc-deficient thymocytes, which fail to progress beyond the DN2 thymic niche, ADA-deficient thymocytes are able to progress through thymic ontogeny when the thymic microenvironment is sufficiently metabolically detoxified,[@bib24] thereby providing a possible tumor suppressor effect in more distal thymic niches by competing with transduced cells carrying insertional proto-oncogene activation events ([Figure 6](#fig6){ref-type="fig"}). While alternative hypotheses exist to explain the differing risk of oncogenesis in early gene therapy trials for SCID-X1 and ADA-SCID, none provide a unifying conceptual framework. For SCID-X1 these include evidence for cooperativity between *Lmo2* and γc expression in the thymus with double transgenic mice showing accelerated development of T cell malignancy, strikingly in association with *Notch1* mutations.[@bib25] For ADA-SCID, these include the possibility that the progenitors transduced in bulk CD34^+^ populations might be more differentiated than for SCID-X1, and that the level of vector-encoded ADA expression might be insufficient to support the development of a T cell leukemic phenotype, which has been shown to be associated with increased ADA expression.[@bib26] Another notable difference between these two gene therapy trials was the use of sub-ablative busulfan conditioning in ADA-SCID patients, which is known to increase the level of bone marrow engraftment.[@bib27] It is therefore conceivable that increased bone marrow engraftment may lead to increased thymic seeding with a resultant reduction in oncogenic risk. Increasing the level of myeloablative condition in our model might also reduce the incidence of malignancy for a given cell dose. A further challenge is to reconcile the concept of cell competition as a tumor suppressor mechanism in the thymus with the occurrence of T cell leukemias in a gene therapy trial for Wiskott-Aldrich syndrome (WAS) using a conventional γ-retroviral vector.[@bib20] Six of ten treated patients developed T-ALL with dominant *LMO2* clones identified in each case. Several of the leukemias also had secondary mutations in the proto-oncogenes *TAL1* and *LYL1*, both of which are known to be associated with T-ALL. Similar to ADA-SCID, there is no absolute block to T cell ontogeny in the thymus in WAS, although abnormalities of T cell development have been implicated in this condition.[@bib28], [@bib29], [@bib30] Of particular relevance, the WAS protein (WASP) has been shown to be important for double-negative to double-positive cell transition that may partly be explained by reduced cycling of DN3 cells. Further, it has been suggested that in the absence of WASP, the decreased migratory responses and increased percentage of single positive cells implies retention of these cells in the thymus.[@bib29] It therefore remains plausible that this could result in reduced competitive pressure on thymocytes rendered pre-leukemic by insertional proto-oncogene activation. Data derived from our model are certainly consistent with this possibility given our demonstration that lymphoid oncogenesis does not require a complete block in bone marrow progenitor supply and, at least in mice, is observed at wild-type progenitor cell doses that are sufficiently high to reconstitute the peripheral T cell compartment. Ultimately the hypothesis that ADA and WAS protein-deficient thymocytes have differing capacities to act as tumor suppressors in the thymus, through cellular competition, requires experimental evaluation and could be addressed in the model system we describe in the current report using γc-deficient cells.

Ultimately, despite evidence that insertional proto-oncogene activation was necessary, but not sufficient, for development of T cell leukemias in early gene therapy trials for SCID-X1, the second hit events required for transformation, which we hypothesize are suppressed by cellular competition, show considerable similarity in mice and humans, most notably activating mutations in the PEST domain of NOTCH1.[@bib3], [@bib4] These, predominantly frameshift, mutations result in the production of a truncated protein and persistent activation of Notch1 downstream targets[@bib5], [@bib31], [@bib32] and are consistent with those identified in our previous gene therapy model.[@bib5] Interestingly, in contrast to the findings of Martins et al.,[@bib10] mutations in the HD or TAD domains were not present in our samples. This is likely due to the *Notch1* 5′ deletion being functionally similar to a HD mutation (see below); thus, the presence of a 5′ deletion and HD mutation in the same cell would be mechanistically redundant.[@bib33] Finally, consistent with the strong association of *Notch1* mutations and cases of T cell leukemia and lymphoma[@bib34] in the two malignancies not expressing T cell-surface markers (m249 and m250), *Notch1* mutations could not be detected by sequencing amplicon clones. This was in contrast to observations by Martins et al., where all leukemias had an immature CD8 single-positive (ISP)/double-positive (DP)-like surface phenotype[@bib10] and possibly reflect inherent differences between these two models, notably the source of thymic progenitors being either whole thymus or, in our model, more immature bone marrow progenitor cells.

In samples with the 5′ deletion, an aberrant *Notch1* mRNA initiated from a cryptic promoter in exon 25 produces an active intracellular Notch1 protein that is independent of ligand binding and γ-secretase cleavage[@bib35], [@bib36], [@bib37] and therefore constitutively expressed ([Figure 5](#fig5){ref-type="fig"}A). These mutations have been shown to result from illegitimate V(D)J recombination[@bib36] and, in our study, may have arisen from a failure of cells to exit the thymus as a result of reduced progenitor cell supply. Notably, although 5′ deletions in *NOTCH1* were not identified in SCID-X1 patient samples, they did contain deletions in the tumor suppressor gene locus cyclin-dependent kinase inhibitor 2A (*CDKN2A*), also shown to be the consequence of aberrant V(D)J recombination;[@bib33] however, similar *Cdkn2a* deletions were not found in the six tumor genomes analyzed by WGS in this study. Further evidence of illegitimate V(D)J recombination was identified in our model by whole-genome sequencing, where both α/β and γ/δ recombination events were present in all six tumor genomes analyzed (data not shown). This is in keeping with the observation that the T-ALL that developed in some patients in the SCID-X1 trials arose from both the α/β and γ/δ T cell populations.

In summary, our studies support the role of regenerating thymic precursors in the thymus leading to further genetic abnormalities that predispose to cancer. These findings help explain the differences in cancer risk in diseases treated with gene therapy based on the relative size of the thymic precursor pool and the need for regenerative thymic clones that are predisposed to malignant transformation. Although there is currently no evidence that limiting thymic precursor supply is a risk factor for lymphoid malignancy in humans, our data provide a compelling conceptual framework that could explain why T cell leukemia was observed in early SCID-X1 trials but not in ADA-SCID patients, despite both groups containing integrations near proto-oncogenes such as *LMO2*.

Materials and Methods {#sec4}
=====================

Animals {#sec4.1}
-------

IL2RG^−/−^ mice[@bib12] were obtained from The Jackson Laboratory, γc^−/−^Rag2^−/−^ mice were kindly provided by Professor Stephen Nutt (Walter and Eliza Hall Institute, Parkville, Australia), and C57BL/6 mice were obtained from the Animal Resources Centre (ARC). All experimental procedures were approved by the Animal Ethics Committee of the Children's Medical Research Institute and The Children's Hospital at Westmead.

Progenitor Cell Isolation and Transplantation {#sec4.2}
---------------------------------------------

Recipient γc^−/−^Rag2^−/−^ mice were exposed to sublethal (6 Gy) irradiation using a Gammacell 40 Exactor (MDS Nordion). Bone marrow was harvested from 8- to 10-week-old IL2RG^−/−^, C57BL/6, or C57BL/6 Ly5.1 congenic mice, and Sca1^+^ progenitor cells were isolated using the EasySep SCA1 positive selection kit (STEMCELL Technologies), resuspended in 200 μL RPMI 1640 medium (Life Technologies) and injected intravenously into recipient mice via the tail vein.

Analysis of TCR Repertoire and CDR3 Spectratyping {#sec4.3}
-------------------------------------------------

At 15 weeks post-transplantation, individual TCR V~β~ families in peripheral blood were detected using qRT-PCR and primers specific for the TCR β chain.[@bib38] All analyses were performed in triplicate as previously described.[@bib39] The TCRVβ repertoire diversity of the six most highly represented TCR V~β~ families was subsequently analyzed by CDR3 spectratyping as outlined previously.[@bib38]

Quantitation of Signal Joint T Cell Receptor Excision Circles {#sec4.4}
-------------------------------------------------------------

At 16 weeks post-transplantation, T cells from reconstituted mice were separated using the EasySep Mouse CD90.2/Thy 1.2 Positive Selection Kit (STEMCELL Technologies) and genomic DNA isolated using the Gentra Puregene cell kit (QIAGEN). Signal joint T cell excision circles (sjTREC) were detected by using real-time qPCR with the following primer and probe set; forward 5′-CATTGCCTTTGAACCAAGCTG-3′; reverse, 5′-TTATGCATAGGGTGCAGGTG-3′; probe 5′-FAM-CGGCAGGGTTTTTGTAAAGGTGCTCACTT-QSY-3′.[@bib40] Reactions were performed on a Rotor-Gene 6000 (QIAGEN), and the number of sjTREC within each sample was determined by using the comparative C~t~ method and a sample containing a known number of sjTREC copies, diluted in murine 3T3 cell genomic DNA. The constant gene segment of the *TCRA* gene (Cα) was used to compensate for variations in input DNA with the following primer and probe set: forward 5′-TGACTCCCAAATCAATGTG-3′; reverse, 5′-GCAGGTGAAGCTTGTCTG-3′; probe 5′-FAM-TGCTGGACATGAAAGCTATGGA-QSY-3′.[@bib41]

Flow Cytometric Analysis {#sec4.5}
------------------------

Cells from the bone marrow, thymus, spleen, liver, and peripheral blood were stained and analyzed on a FACSCanto (BD Biosciences) running FACSDiva (v.6.1.3) and FlowJo (v.7.6.1, FlowJo LLC) software. Lymphocytes were identified and gated based on their forward-scattered light (FSC) and side-scattered light (SSC) profiles. Cell suspensions were treated with ACK lysis buffer (150 mmol/L NH~4~Cl, 10 mmol/L KHCO~3~, and 0.1 mmol/L disodium EDTA) and then stained with the following conjugated antibodies: B220-APC-Cy7 (BD Biosciences), CD2-FITC (BD Biosciences), CD3ε-PE (BD Biosciences), CD3ε-Alexaflore 647 (BD Biosciences), CD4-FITC (Caltag Laboratories), CD8a-APC (Caltag Laboratories), CD8a-Alexaflore 647 (BD Biosciences), CD25-FITC (BD Biosciences), CD44-PE (BD Biosciences), CD45-APC (BD Biosciences), Ki-67-FITC (BD Biosciences), Ly5.1-PerCP-Cy5.5 (BD Biosciences), Ly5.2-PerCP-Cy5.5 (BD Biosciences), NK1.1-APC (Caltag Laboratories), and Sca1-Alexaflore 647 (BD Biosciences).

Histology {#sec4.6}
---------

Tissue was dissected from C57BL/6 control or transplanted γc^−/−^Rag2^−/−^ recipient mice and fixed in 10% buffered formalin (Sigma-Aldrich). Paraffin-embedded sections (5 μm) were stained with H&E and evaluated by light microscopy. Images were captured from a Zeiss Axio Imager.A1 Microscope (Carl Zeiss MicroImaging) using a Spot enhanced camera (Diagnostic Instruments, SciTech) running Spot Software (v.4.0.1).

qPCR to Determine Leukemic Origin {#sec4.7}
---------------------------------

To determine whether malignancies were donor or recipient in origin, genomic DNA was isolated using the Gentra Puregene cell kit and qPCR performed using primers to either the human γc (5′-CTTTATTGATAACGATCTATATCCCTCACCC-3′ and 5′-CTCCACTCTGCAGAGTCTATGGAATCC-3′) or bacterial neomycin phospho-transferase (5′-CTTGGGTGGAGAGGCTATTC-3′ and 5′-AGGTGAGATGACAGGAGATC-3′) gene. Reactions were performed on a RotorGene 6000 (QIAGEN) using the QuantiTect SYBR Green PCR kit (QIAGEN) and standardized using primers to the murine *titin* gene (5′-AAAACGAGCAGTGACGTGAGC-3′ and 5′-TTCAGTCATGCTGCTAGCGC-3′) by the comparative Ct method.

Primary Sequence Analysis and Variation Detection {#sec4.8}
-------------------------------------------------

Genomic DNA from six lymphoid tumors and one control sample of C57BL/6 Sca1^+^ progenitor cells were sequenced at the Beijing Genomics Institute (BGI), using HiSeq2000. Whole-genome sequencing was achieved to 30 times coverage and a comparative analysis between the control sample and the tumors, to call tumor-specific somatic single nucleotide variants (SNVs), somatic copy number variations (CNVs), short insertions/deletions (InDels), and structure variant (SV) mutations, was performed. BGI's cancer genomics bioinformatics pipeline was applied for sequencing analysis and variation detection (<http://www.bgitechsolutions.com/>). Paired-end reads were aligned by Burrows-Wheeler aligner (BWA)[@bib42] to the mouse mm9 reference genome. All BAM files were processed to identify duplicates using the Picard MarkDuplicates tool from the Broad Institute. SNVs were detected using VarScan,[@bib43] InDels were called by SAMtools,[@bib44] CNVs were called by BGI's proprietary method CNV_Detection, and SVs were called by CREST.[@bib45] Copy number ratios \<0.5 were considered as deletions and \>1.5 as amplifications. ANNOVAR software[@bib46] was used to annotate the variant results. The Integrative Genomics Viewer (IGV) 2.3[@bib47] was used to visually inspect sequence reads. BAM files and associated metadata in XML format have been uploaded to the European Nucleotide Archive (ENA; <http://www.ebi.ac.uk/ena>) under the study identification number PRJEB8006.

Gene Expression Arrays {#sec4.9}
----------------------

Total RNA for expression analysis was isolated using the RNeasy Mini Kit (QIAGEN), and transcriptome profiling was performed by The Ramaciotti Centre for Gene Function Analysis (University of New South Wales). Briefly, total RNA samples (500 ng/sample) were amplified and labeled according to the manufacturer's instructions (Affymetrix). Amplified RNA was quantified using a NanoDrop (Thermo Scientific) and distribution of the amplified material was analyzed in a 2100 Bioanalyzer (Agilent). Amplified cRNA was hybridized onto Affymetrix mouse 2.1 gene arrays; the arrays were scanned and expression measurements extracted using the Affymetrix Expression Console v.1.3 software. Microarray data have been deposited at ArrayExpress (<http://www.ebi.ac.uk/arrayexpress/>) under the accession number [E-MTAB-3159](array-express:E-MTAB-3159){#intref0030}.

Gene Expression Data Analysis {#sec4.10}
-----------------------------

Robust Multi-array Average (RMA) was applied to normalize the expression data,[@bib48] and the remaining analysis was carried out using *Bioconductor* package[@bib49] in the R statistical language 3.01. Empirical Bayes statistics for differential expression were calculated using *limma* 3.16.6.[@bib50] p values were adjusted by Benjamini & Hochberg's method to account for multiple test correction.[@bib51] Genes with expression change ≥2-fold and adjusted p value (FDR) ≤0.05 were considered as differentially expressed.

Identification of *Notch1* Gene Mutations and Structural Variations {#sec4.11}
-------------------------------------------------------------------

Mutations within the PEST, TAD, or HD domains of *Notch1* were identified by sequencing PCR products amplified using *Pfu* DNA polymerase (Promega). Primers spanning exons 26, 27, and 34, where the HD, TAD, and PEST domains are located, are described elsewhere.[@bib31] The presence of structural variations in *Notch1* identified by WAS was confirmed by PCR amplification using Phusion high-fidelity DNA polymerase (New England Biolabs) and primers adjacent to the 5′ and 3′ break points (5′- CAGTCAGGAGTGGTGGATCC-3′ and 5′-GGCTTGGTCTAGTGCTCCTG-3′). In cases where the PCR product contained more than one amplicon, the PCR product was cloned into pGEM-T Easy (Promega), and the sequence of individual clones was determined.

qRT-PCR for *Notch1* Downstream Targets {#sec4.12}
---------------------------------------

Total RNA was extracted using the RNeasy mini kit (QIAGEN) from lymphoblastic cells or from wild-type thymocytes and cDNA synthesized from 1 μg total RNA by using the Superscript III first-strand synthesis Supermix kit (Life Technologies). To determine whether mutations in *Notch1* affected expression of downstream target genes, qRT-PCR was performed on a RotorGene 6000 using *c-myc* (5′-CTGTTTGAAGGCTGGATTTCCT-3′ and 5′-CAGCACCGACAGACGCC-3′), *Dtx1* (5′-TGCCTGGTGGCCATGTACT-3′ and 5′-GACACTGCAGGCTGCCATC-3′), and *Hes1* (5′-AAGACGGCCTCTGAGCACA-3′ and 5′-CCTTCGCCTCTTCTCCATGAT-3′) primers[@bib52] using the Brilliant III Ultrafast SYBR green QPCR master mix (Agilent Technologies). Expression levels were standardized using primers to the β-actin gene (5′- CTAGACTTCGAGCAGGAGATGGC-3′ and 5′- TCTGCATCCTGTCAGCAATGCC-3′) by the comparative Ct method.

Statistical Analysis {#sec4.13}
--------------------

Results were analyzed by the Wilcoxon rank-sum (Mann-Whitney) (<http://www.socscistatistics.com/tests/mannwhitney/default2.aspx>) or Fisher's exact test (<http://www.graphpad.com/quickcalcs/contingency1.cfm>). For comparison of population survival, cohorts of mice were evaluated using Kaplan-Meier analysis (GraphPad Prism v.5.04). Values represent the mean ± SEM and results considered significant when p \< 0.05.
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![Incidence and Latency of Lymphoid Malignancies Observed under Conditions of Limiting Bone Marrow Progenitor Supply\
(A) Experimental design. (B) Kaplan-Meier survival analysis at 18 months post-transplantation; animals receiving high, mid, and low wild-type γc-expressing cell doses are indicated in blue, green, and red, respectively. (C) H&E staining of C57BL/6 control (top panels) or malignant samples from an animal receiving the low-dose of γc-expressing progenitors (bottom panels, m209). Scale bar, 100 μm.](gr1){#fig1}

![Immunological Reconstitution and T Cell Diversity under Conditions of Limiting Bone Marrow Progenitor Supply\
(A) Total white cell counts were determined using peripheral blood samples taken from the tail vein at 16 weeks post-transplantation. Subset analysis was performed by staining with antibodies against murine CD2, CD3, CD45, B220, and NK1.1 and flow cytometric analysis. Data show mean ± SEM; n = 32, 31, and 30 for the high, mid, and low wild-type doses, respectively. (B) Peripheral blood was taken from mice at 15 weeks post-transplantation, and TCR V~β~ repertoire analysis was performed by qRT-PCR. The percentage of each TCR V~β~ family is indicated with results representing the mean of triplicate values for each group (n = 3). (C) CDR3 spectratypes of TCR V~β~ 13-2, 16, and 19 families in reconstituted mice transplanted with each of the three wild-type cell doses as indicated. (D) Quantitation of sjTREC in purified T cell populations from the spleen, 15 weeks following transplantation. Blue bars, high γc-expressing cell dose (5 × 10^5^ cells); green bars, mid γc-expressing cell dose (5 × 10^4^); red bars, low γc-expressing cell dose (5 × 10^3^ cells).](gr2){#fig2}

![Thymic Size and Composition under Conditions of Limiting Bone Marrow Progenitor Supply\
(A) Size of the thymocyte population at 6 weeks post-transplantation in C57BL/6 control animals (black bar) or mice receiving either the high (blue bar) or low-dose (red bar) of γc-expressing progenitor cells. (B) Percentages of early T cells within the thymus at 6 weeks post-transplantation in age-matched controls and animals receiving the high or low dose of γc-expressing progenitors; DN, blue; DP, green; SP CD8^+^, red; SP CD4^+^, purple. (C) Percentages of cells within the DN niche at 6 weeks post-transplantation in age-matched controls and animals receiving the high or low dose of wild-type progenitors; DN1, darkest blue; DN2, mid blue; DN3, light blue; DN4, dark blue. (D) Ratios of cells in the DN niches (DN2:DN1, DN3:DN2, and DN4:DN3) at 6 weeks post-transplantation in age-matched controls (black bars) and animals receiving the high (blue bars) or low (red bars) dose of wild-type progenitors. Values represent the mean ± SEM with n = 7, 6, and 6 for age-matched controls and high and low γc-expressing progenitor cell doses, respectively.](gr3){#fig3}

![Whole-Genome Sequence Analysis of Selected Lymphoid Malignancies\
Circos plots representing six malignant genomes are shown with notable mutations (somatic SNVs and InDels) compared to wild-type Sca1^+^ progenitors indicated. The three circles in each plot, from outermost inward, represent the mouse chromosomes, copy number alterations (red dots \>1.5-fold, green dots \<0.5-fold), and structural rearrangements (rearrangement types are depicted with different colors, indicated under the bottom panel). Genes with SNV (red) and small InDels (black) are labeled on the circos plots, except for mutations in Chr8 and Chr11 of m313 owing to space limitations. An asterisk indicates InDels identified in the PEST domain of *Notch1*.](gr4){#fig4}

![Molecular Analysis of Lymphoid Malignancies Observed under Conditions of Limiting Bone Marrow Progenitor Supply\
(A) Schematic representation of murine *Notch1* indicating the position of the 5′ deletion (Δ5′) and activating mutations in exon 34 affecting the PEST domain (triangles). The numbers of malignancies with exon 34 mutations are indicated; white, frameshift deletions; gray, frameshift addition; black, single nucleotide substitution resulting in a premature stop codon. The location of a cryptic promoter (exon 25) is designated by the arrow. (B) Graph showing the frequency and type of *Notch1* mutations (Δ5′ and/or PEST domain) identified in T cell malignancies at the low (n = 9) and mid (n = 3) wild-type progenitor cell doses. ND, not detected. (C) The *Notch1* germline sequence flanking exons 1 and 2 is indicated in the top row and samples, with evidence of N nucleotide addition (in lower case), shown below. Sequences in red rectangles are heptamer- (CACAGTG) or nonamer-like (ACAAAAACC) motifs separated by 12- or 23-bp spacers and asterisks indicate canonical nucleotide residues.[@bib53] Arrows designate the sites of *Rag*-mediated DNA breakage.](gr5){#fig5}

![Hypothetical Models of Competitive and Impaired Replacement in γc-Deficient Mice and Human Clinical Trials of ADA-SCID and SCID-X1, where the Acquisition of an At-Risk Phenotype May Lead to Malignant Transformation\
(A) The thymus is continuously supplied from the bone marrow when transplanted with a high dose of wild-type cells, thereby replacing thymus-resident progenitor cells. When a low dose of wild-type cells are transplanted; however, there is reduced competition possibly leading to self-renewal of thymus-resident progenitors, increased residence time in the thymus, and the potential to acquire additional genomic mutations such as those observed in *Notch1*. (B). In ADA-SCID, cells containing deleterious integrations migrate out of the thymus by normal cellular replacement, because cells that are not gene-modified are capable of progressing past the DN2 niche. For SCID-X1, however, cells containing similar integrations in *LMO2* may have self-renewal potential. These cells could then be retained in the thymus for extended time periods because of reduced progenitor cell migration (because cells that have not been gene-corrected are unable to progress past the DN2 niche due to a lack of interleukin-7 \[IL-7\] signaling) and may acquire additional genetic lesions in some patients.](gr6){#fig6}

###### 

Latency and Cellular Immunophenotype of Lymphoid Malignancies

  Wild-Type Cell Dose                         Mouse   Latency (Months)                  Immunophenotype                   Thymus Weight (g)[a](#tblfn1){ref-type="table-fn"}
  ------------------------------------------- ------- --------------------------------- --------------------------------- ----------------------------------------------------
  5 × 10^4^                                   50      12.7                              CD3^+^ CD4^--^ CD8^--^ B220^--^   ND
  91 (313[b](#tblfn2){ref-type="table-fn"})   9.5     CD3^+^ CD4^+^ CD8^+^ B220^+^      ND                                
  97[b](#tblfn2){ref-type="table-fn"}         11.2    CD3^+^ CD4^--^ CD8^+^ B220^--^    0.11                              
  249                                         17.6    CD3^--^ CD4^--^ CD8^--^ B220^+^   ND                                
  5 × 10^3^                                   133     9.0                               CD3^+^ CD4^+^ CD8^+^ B220^+^      0.18
  137[b](#tblfn2){ref-type="table-fn"}        6.8     CD3^--^ CD4^+^ CD8^+^ B220^--^    0.68                              
  183                                         7.5     CD3^+^ CD4^+^ CD8^+^ B220^--^     0.56                              
  189[b](#tblfn2){ref-type="table-fn"}        7.7     CD3^--^ CD4^+^ CD8^+^ B220^--^    0.19                              
  191[b](#tblfn2){ref-type="table-fn"}        8.0     CD3^+^ CD4^+^ CD8^+^ B220^+^      0.48                              
  192                                         10.0    CD3^+^ CD4^+^ CD8^+^ B220^--^     0.76                              
  209[b](#tblfn2){ref-type="table-fn"}        9.1     CD3^+^ CD4^+^ CD8^+^ B220^--^     0.80                              
  215                                         10.3    CD3^--^ CD4^+^ CD8^--^ B220^--^   0.29                              
  250                                         10.9    CD3^--^ CD4^--^ CD8^--^ B220^+^   ND                                
  258                                         10.0    CD3^+^ CD4^+^ CD8^+^ B220^--^     0.56                              

ND, not macroscopically detectable.

Wild-type C57BL/6 thymus is 0.05 g ± 0.002 g (n = 20).

Whole-genome massively parallel sequencing performed; m313 is the secondary recipient of m91 leukemic blasts.

###### 

Summary of *Notch1* Mutations Identified in Lymphoid Malignancies

  Wild-Type Cell Dose                   Mouse                                  5′ Deletion (Δ5′)                         Exon 34 Mutation[a](#tblfn3){ref-type="table-fn"}
  ------------------------------------- -------------------------------------- ----------------------------------------- ---------------------------------------------------
  5 × 10^4^                             50                                     ND                                        ND
  91                                    ND                                     ND                                        
  97                                    yes                                    ND                                        
  249                                   ND                                     ND                                        
  5 × 10^3^                             133                                    yes                                       G \> T 7172, insertion TTAC 7173
  137                                   yes[b](#tblfn4){ref-type="table-fn"}   insertion CA 7283, G \> C 7284            
  183                                   yes[b](#tblfn4){ref-type="table-fn"}   C \> T 7345                               
  189                                   yes                                    G \> C 7172, insertion ACCT 7173          
  191                                   ND                                     G \> A 7284, insertion AATCGAAGGGC 7285   
  192                                   yes                                    ND                                        
  209                                   yes                                    insertion AGTCTGAAGA 7362                 
  215                                   ND                                     insertion T 7146                          
  250                                   ND                                     ND                                        
  258                                   yes                                    deletion CA 7476                          
  NA[c](#tblfn5){ref-type="table-fn"}   313                                    yes                                       insertion CA 7283, G \> C 7284

ND, not detected by sequencing amplicon clones; NA, not applicable.

Frameshift mutations all result in the introduction of a premature stop codon and associated loss of the PEST domain; indicated position is relative to GenBank accession [AB100603.1](ncbi-n:AB100603.1){#intref0050}. Mutations were not identified in the HD or TAD domains.

Two break points were identified.

m313 is the secondary recipient of m91 leukemic blasts.

[^1]: Present address: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Centre for Cancer Bioinformatics, Peking University Cancer Hospital & Institute, 52 Fu Cheng Road, Hai Dian District, Beijing 100142, China.
